A Phase I/II, Open-Label, Prospective, Multicenter Study to Evaluate the Efficacy and Safety of Lower Doses of Bortezomib Plus Busulfan and Melphalan as a Conditioning Regimen in Patients with Multiple Myeloma Undergoing Autologous Peripheral Blood Stem Cell Transplantation: The KMM103 Study-Reference-Cited by-同舟云学术

A Phase I/II, Open-Label, Prospective, Multicenter Study to Evaluate the Efficacy and Safety of Lower Doses of Bortezomib Plus Busulfan and Melphalan as a Conditioning Regimen in Patients with Multiple Myeloma Undergoing Autologous Peripheral Blood Stem Cell Transplantation: The KMM103 Study

Published:2019-07 Issue:7 Volume:25 Page:1312-1319
ISSN:1083-8791
Container-title:Biology of Blood and Marrow Transplantation
language:en
Short-container-title:Biology of Blood and Marrow Transplantation

Author:

Park Sung-Soo^ORCID,Kim Kihyun,Kim Seok-Jin,Lee Jae Hoon,Yoon Sung Soo,Mun Yeung Chul,Lee Je-Jung,Eom Hyeon-Seok,Kim Jin Seok^ORCID,Min Chang-Ki

Publisher

Elsevier BV

Subject

Transplantation,Hematology

Reference37 articles.

1. Comparison of 200 mg/m2 melphalan and 8 Gy total body irradiation plus 140 mg/m2 melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myelome 9502 randomized trial

2. The role of hematopoietic stem cell transplantation in the treatment of multiple myeloma;Bensinger;J Natl Compr Canc Netw,2004

3. High-dose melphalan versus busulfan, cyclophosphamide, and etoposide as preparative regimens for autologous stem cell transplantation in patients with multiple myeloma;Benson;Leuk Res,2007

4. Busulfan 12 mg/kg plus melphalan 140 mg/m2 versus melphalan 200 mg/m2 as conditioning regimens for autologous transplantation in newly diagnosed multiple myeloma patients included in the PETHEMA/GEM2000 study;Lahuerta;Haematologica,2010

5. High-dose idarubicin, cyclophosphamide and melphalan as conditioning for autologous stem cell transplantation increases treatment-related mortality in patients with multiple myeloma: results of a randomised study;Fenk;Br J Haematol,2005

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prognostic value of low muscle mass at the 12<sup>th</sup> thoracic vertebral level in multiple myeloma treated with transplantation: CAREMM-2101 study;Diagnostic and Interventional Radiology;2023-07-01

2. Busulfan plus melphalan versus high-dose melphalan as a conditioning regimen for autologous stem cell transplantation in multiple myeloma with high-risk features (KMM 2015);Annals of Hematology;2023-07-01

3. Using Odontoblasts Derived from Dog Endometrial Stem Cells Encapsulated in Fibrin Gel Associated with BMP-2 in a Rat Pulp-Capping Model;Current Issues in Molecular Biology;2023-04-03

4. Mexican Consensus of Multiple Myeloma;Gaceta de M�xico;2020-10-27

5. Busulfan, melphalan, and bortezomib compared to melphalan as a high dose regimen for autologous hematopoietic stem cell transplantation in multiple myeloma: long term follow up of a novel high dose regimen;Leukemia & Lymphoma;2020-08-31